<div id="readability-page-1"><p>MannKind Corporation (NASDAQ:MNKD - Get Free Report)'s stock price was down 6.6% on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock traded as low as $3.03 and last traded at $3.0650. Approximately 1,435,401 shares were traded  during mid-day trading, a decline of 72% from the average daily volume of 5,144,097 shares. The stock had previously closed at $3.28.</p><p>MNKD has been the topic of a number of other reports. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of MannKind in a research note on Thursday, January 22nd. Leerink Partners began coverage on shares of MannKind in a research report on Thursday, November 13th. They set an &#34;outperform&#34; rating and a $7.00 target price on the stock. Royal Bank Of Canada  reaffirmed a &#34;sector perform&#34; rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a research note on Friday. Truist Financial  set a $9.00 price objective on shares of MannKind in a research note on Monday, November 24th. Finally, HC Wainwright  reissued a &#34;buy&#34; rating and set a $11.00 price objective on shares of MannKind in a report on Wednesday, February 25th. One investment analyst  has rated the stock with a Strong Buy rating, five have assigned  a Buy rating and three have assigned  a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $9.21.</p><p><b>Check Out Our Latest Stock Report on MNKD</b></p><h2>Insider Buying and Selling at MannKind</h2><p>In other MannKind news, insider Stuart A. Tross sold 47,006 shares of the company's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the transaction, the insider directly owned 985,007 shares in the company, valued at approximately $6,235,094.31. This represents a 4.55% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Michael Castagna sold 65,804 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total transaction of $395,482.04. Following the transaction, the chief executive officer directly owned 2,504,792 shares in the company, valued at $15,053,799.92. The trade was a 2.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 262,846 shares of company stock worth $1,546,840 over the last 90 days. Company insiders own  2.70% of the company's stock. </p><h2>Institutional Investors Weigh In On MannKind</h2><p>Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of  MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company's stock valued at $278,000 after purchasing an additional 9,160 shares during the period.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of  MannKind by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company's stock worth $1,059,000 after acquiring an additional 6,079 shares during the period.  UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of  MannKind by 8.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company's stock worth $3,374,000 after acquiring an additional 53,202 shares during the period.  Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of  MannKind in the second quarter worth approximately $42,000.  Finally, Teacher Retirement System of Texas grew its holdings in  MannKind by 4.7% in the second quarter. Teacher Retirement System of Texas now owns 77,726 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 3,506 shares during the period. Institutional investors and hedge funds own  49.55% of the company's stock. </p><h2>MannKind Stock Down 6.7%</h2><p>The business's fifty day moving average is $5.55 and its 200-day moving average is $5.37. The stock has a market capitalization of $939.94 million, a PE ratio of 153.33 and a beta of 0.84. </p><p>MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.04). The company had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The firm's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 EPS.  As a group, sell-side analysts anticipate that  MannKind Corporation will post 0.1 EPS for the current fiscal year. </p><h2>MannKind Company Profile</h2> (Get Free Report)<p>MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.  </p><p>Afrezza received U.S.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than MannKind</li><li>Silver Crossed $100: Is the $500 surge next? (Join us March 4)</li><li>3 Signs You May Want to Switch Financial Advisors</li><li>ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!</li><li>America’s 1776 happening again</li><li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MannKind Right Now?</h2><p>Before you consider MannKind, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p><p>While MannKind currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MNKD

<p>MannKind Corporation's stock (NASDAQ:MNKD) fell 6.6% following a downgrade from Wall Street Zen, shifting from a buy to a hold rating. The stock traded as low as $3.03, with a significant drop in trading volume. Analysts have mixed ratings, with one strong buy, five buys, and three holds, leading to a consensus rating of "Moderate Buy" and a target price of $9.21. Recent insider sales and institutional investments reflect ongoing interest in the company, which reported a revenue increase of 45.8% in its last earnings report.</p>

MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade